论文部分内容阅读
本文采用随机对照开放临床试验,对乳酸环丙沙星(Ciprofloxacin,CPLX)注射剂进行了临床评价,共治疗各种细菌性感染100例,其中50例与头孢噻肟钠(Cefotaxime,CTX)相对照。结果显示CPLX组与对照CTX组疗效各为91.0％和92.0％(P>0.05),无显著性差异。两组细菌清除率各为90,8％和88.6％(P>0.05),无显著性差异。不良反应分别为15％和8％。不良反应程度轻微,主要表现为注射局部反应和消化道反应,其中注射局部反应CPLX略高于CTX。体外抗菌活性表明CPLX对大多数革兰氏阴性菌和革兰氏阳性菌具有良好的抗菌活性。
In this randomized controlled clinical trial, 100 cases of various bacterial infections were treated with Ciprofloxacin (CPLX) injection, of which 50 cases were compared with Cefotaxime (CTX) . The results showed that the efficacy of CPLX group and control CTX group were 91.0% and 92.0% (P> 0.05), no significant difference. The bacterial clearance rates of the two groups were 90.8% and 88.6%, respectively (P> 0.05), with no significant difference. Adverse reactions were 15% and 8% respectively. Minor adverse reactions, mainly for the injection of local reactions and gastrointestinal reactions, including injection of local response CPLX slightly higher than CTX. In vitro antibacterial activity indicates that CPLX has good antibacterial activity against most Gram-negative and Gram-positive bacteria.